Increased PD-L1 expression in breast and colon cancer stem cells

被引：99

作者：

Wu, Yanheng ^{[1
]}

Chen, Mingshui ^{[1
,2
,3
]}

Wu, Peihong ^{[4
,5
]}

Chen, Chen ^{[6
]}

Xu, Zhi Ping ^{[1
]}

Gu, Wenyi ^{[1
]}

机构：

[1] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Bldg 75,Cooper Rd, Brisbane, Qld 4072, Australia

[2] Fujian Prov Canc Hosp & Inst, Lab Immunooncol, Dept Med Oncol, Fuzhou, Peoples R China

[3] Fujian Prov Key Lab Translat Canc Med, Fuzhou, Peoples R China

[4] Sun Yat Sen Univ, Dept Med Imaging & Intervent Radiol, Ctr Canc, Guangzhou, Guangdong, Peoples R China

[5] Sun Yat Sen Univ, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China

[6] Univ Queensland, Sch Biomed Sci, Brisbane, Qld, Australia

来源：

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | 2017年 / 44卷 / 05期

关键词：

CLINICAL-SIGNIFICANCE; SELF-RENEWAL; PATHWAY; SAFETY;

D O I：

10.1111/1440-1681.12732

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Here we report the expression of programmed cell death ligand 1/2 (PD-L1/L2) in breast and colon cancer stem cells (CSCs). The stemness of these cells was confirmed by their surface markers. Using flow cytometry analysis we demonstrated that PD-L1 expression was higher in CSCs of both cancers compared to non-stem like cancer cells. Consistent with this, detection of cellular PD-L1 proteins by western blot assay also showed increased PD-L1 protein in CSCs. In contrast, only trace amounts of PD-L2 were detected in CSCs of both cancers. Our results suggest that breast and colon cancers may be sensitive to PD1/PD-L1 immunotherapy and thus warrant further investigations of CSC targeted PD1/PD-L1 therapy.

引用

页码：602 / 604

页数：3

共 12 条

[1] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[2] Co-expression of CD133+/CD44+ in human colon cancer and liver metastasis [J].

Bellizzi, Antonia ;

Sebastian, Sinto ;

Ceglia, Pasquale ;

Centonze, Matteo ;

Divella, Rosa ;

Manzillo, Elvira Foglia ;

Azzariti, Amalia ;

Silvestris, Nicola ;

Montemurro, Severino ;

Caliandro, Cosimo ;

De Luca, Raffaele ;

Cicero, Giuseppe ;

Rizzo, Sergio ;

Russo, Antonio ;

Quaranta, Michele ;

Simone, Giovanni ;

Paradiso, Angelo .

JOURNAL OF CELLULAR PHYSIOLOGY, 2013, 228 (02) :408-415

[3] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[4] PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells [J].

Chen, Jiezhong ;

Shao, Renfu ;

Li, Feng ;

Monteiro, Michael ;

Liu, Jun-Ping ;

Xu, Zhi Ping ;

Gu, Wenyi .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2015, 42 (12) :1317-1326

[5] Highly enriched CD133+CD44+ stem-like cells with CD133+CD44high metastatic subset in HCT116 colon cancer cells [J].

Chen, Ke-li ;

Pan, Feng ;

Jiang, Heng ;

Chen, Jian-fang ;

Pei, Li ;

Xie, Fang-wei ;

Liang, Hou-jie .

CLINICAL & EXPERIMENTAL METASTASIS, 2011, 28 (08) :751-763

[6] The cancer stem cell: premises, promises and challenges [J].

Clevers, Hans .

NATURE MEDICINE, 2011, 17 (03) :313-319

[7] Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability [J].

Gu, W. ;

Yeo, E. ;

McMillan, N. ;

Yu, C. .

CANCER GENE THERAPY, 2011, 18 (12) :897-905

[8] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma [J].

Hamid, Omid ;

Robert, Caroline ;

Daud, Adil ;

Hodi, F. Stephen ;

Hwu, Wen-Jen ;

Kefford, Richard ;

Wolchok, Jedd D. ;

Hersey, Peter ;

Joseph, Richard W. ;

Weber, Jeffrey S. ;

Dronca, Roxana ;

Gangadhar, Tara C. ;

Patnaik, Amita ;

Zarour, Hassane ;

Joshua, Anthony M. ;

Gergich, Kevin ;

Elassaiss-Schaap, Jeroen ;

Algazi, Alain ;

Mateus, Christine ;

Boasberg, Peter ;

Tumeh, Paul C. ;

Chmielowski, Bartosz ;

Ebbinghaus, Scot W. ;

Li, Xiaoyun Nicole ;

Kang, S. Peter ;

Ribas, Antoni .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) :134-144

[9] Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer [J].

Nomi, Takeo ;

Sho, Masayuki ;

Akahori, Takahiro ;

Hamada, Kaoru ;

Kubo, Atsushi ;

Kanehiro, Hiromichi ;

Nakamura, Shinji ;

Enomoto, Koji ;

Yagita, Hideo ;

Azuma, Miyuki ;

Nakajima, Yoshiyuki .

CLINICAL CANCER RESEARCH, 2007, 13 (07) :2151-2157

[10] Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer [J].

Ohigashi, Y ;

Sho, M ;

Yamada, Y ;

Tsurui, Y ;

Hamada, K ;

Ikeda, N ;

Mizuno, T ;

Yoriki, R ;

Kashizuka, H ;

Yane, K ;

Tsushima, F ;

Otsuki, N ;

Yagita, H ;

Azuma, M ;

Nakajima, Y .

CLINICAL CANCER RESEARCH, 2005, 11 (08) :2947-2953

← 1 2 →